Liposome-Based Targeted Drug Delivery for the Treatment of Tuberculosis: A Review
Tuberculosis remains a major cause of infectious mortality, and successful treatment requires effective multidrug exposure across heterogeneous disease sites. Conventional administration is complicated by prolonged therapy, adverse effects, variable pharmacokinetics and incomplete access to some intracellular and tissue compartments. Liposomes provide aqueous and lipid domains capable of accommodating antitubercular drugs with different physicochemical properties. Their composition, size and surface characteristics influence drug retention, biological distribution and interaction with macrophages. This narrative review examines the rationale for liposomal treatment of tuberculosis, with particular attention to isoniazid and rifampicin, vesicle architecture, preparation principles, characterization and research evidence. Selected original studies support sustained drug delivery and improved preclinical performance, while recent co-encapsulation work demonstrates continuing interest in coordinated delivery of complementary agents. Nevertheless, cellular uptake, prolonged release and favourable laboratory findings do not independently establish clinical benefit. Major unresolved issues include access to diverse lesion compartments, maintenance of effective drug combinations, storage stability, reproducible manufacture and route-specific tolerability. Clinical experience with inhaled liposomal amikacin in nontuberculous mycobacterial disease provides a relevant platform precedent but does not demonstrate efficacy against tuberculosis. Liposomes should therefore be regarded as investigational tools for improving antitubercular drug delivery, with their therapeutic value dependent on rigorous pharmacological and clinical validation.
Authors
- Vishal S. Madankar
- Rutuja P. Sonune
- Dr. Sampat D. Navale
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-14
- DOI
- https://doi.org/10.5281/zenodo.24216854
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00